CRLS1 (human) review notes
UniProt Q9UJA2, Cardiolipin synthase (CMP-forming), EC 2.7.8.41. Synonyms C20orf155, CLS1, hCLS1.
301 aa, five predicted TM helices, Pfam PF01066 (CDP-OH_P_transf), InterPro IPR000462 /
IPR050324 (CDP-alcohol phosphatidyltransferase class I), PANTHER PTHR14269:SF60.
Process log
- 2026-10-09:
just fetch-gene-pmids human CRLS1 cached the 6 GOA PMIDs. Additionally cached
PMID:20025994 (Nie 2010), PMID:31914590 (Kasahara 2020), PMID:29343430 (Serricchio 2018),
PMID:42414597 (2026 heart Crls1 KO) via just fetch-pmid.
- Deep research:
just deep-research-falcon human CRLS1 --fallback perplexity-lite FAILED.
Falcon timed out after 600 s; the perplexity-lite fallback failed with "Provider 'perplexity'
not available. Available: falcon, asta, openscientist". The review was written from direct
PubMed MCP research and the cached publications. The underlying falcon job nevertheless
completed later (15:56) and wrote CRLS1-deep-research-falcon.md (tool-generated, 69 citations).
On a scan it agrees with this review: CDP-DAG + PG -> CL + CMP is the core activity, and
disease and knockout phenotypes (COXPD57, mouse muscle, heart, macrophage complex II) are
downstream consequences of cardiolipin loss, not additional CRLS1 activities. It does not
discuss the Nie 2010 LPG acyltransferase claim. No review decisions changed.
Molecular function: CDP-type cardiolipin synthase
- Final step of eukaryotic de novo CL synthesis: CDP-DAG + PG -> CL + CMP.
PMID:16716149
- Three independent 2006 groups identified the human gene:
- Houtkooper et al.: complementation of yeast crd1 null; enzyme characterised in mitochondria
of the complemented strain; alkaline pH optimum, divalent-cation requirement.
PMID:16678169
- Chen et al. (Lilly): recombinant enzyme in COS-7 makes CL from CDP-DAG + PG in vitro; mito
localisation by IF and fractionation. PMID:16716149
- Lu et al. (Feingold/Hatch): expression raised CLS activity, specific for CL (no PGP synthase
increase); CL pool increased. PMID:16547353
- It is the CDP-alcohol phosphatidyltransferase (CDP-type) CLS, not the PLD-type
(2 PG -> CL + glycerol; GO:0008808 "cardiolipin synthase activity") found in bacteria and some
protist mitochondria. All MF annotations on CRLS1 (GO:0043337 and its ancestor GO:0016780 via
IPR000462) are on the CDP-type branch; there is no GO:0008808 annotation. Confirmed via
QuickGO that GO:0016780 is an is_a ancestor of GO:0043337 and that GO:0008808 is defined as the
PG + PG reaction.
- Chen et al. 2026 Cell comparative mitoproteome paper: LECA mitochondria likely had both
CDP-type and PLD-type CLS, differentially lost; PLD-type CLS is a candidate pathogen target
(absent in humans, essential in P. knowlesi). PMID:42822426
This is comparative/computational context, not evidence for CRLS1's activity.
Disputed secondary activity: LPG acyltransferase
- Nie et al. 2010 (Shi lab, same group as PMID:16716149) reported acyl-CoA-dependent LPG
acyltransferase activity of recombinant and purified hCLS1, independent of CDP-DAG.
PMID:20025994
- This is the basis of the Reactome events R-HSA-1482546 / R-HSA-1482689 ("LPG is acylated to PG by
CRLS1") and R-HSA-1482925 (PG acyl-chain remodelling).
- Caveats: (i) single-lab, apparently not replicated; (ii) mechanistically unusual: CRLS1 is a
CDP-alcohol phosphotransferase with no acyltransferase motif; (iii) the positive control used
(LPGAT1) has since been reassigned (LPLAT7, see genes/human/LPGAT1 review, PMID:36049524), which
weakens confidence in the LPG acyltransferase assay system; (iv) the GO terms Reactome mapped
(GO:0003841, GO:0047144) are lysophosphatidic acid (LPA) acyltransferase activities, a different
substrate from LPG, so these mappings are wrong regardless.
Localisation
- Mitochondrial inner membrane, multipass. [PMID:16547353 UniProt cites for IM];
PMID:16716149
- Mieap paper (PMID:38322995) treats EGFP-CRLS1 as an inner membrane marker and shows it in the
Mieap-depleted phase of Mieap condensates; cites a 700-800 kDa CL synthesis complex.
- Serricchio et al. 2018: PGS1 associates with CLS1 and PTPMT1 in large complexes.
PMID:29343430
(abstract only)
Physiology / disease
- Biallelic CRLS1 variants cause COXPD57: progressive mitochondrial encephalopathy; patient
fibroblasts show reduced CL, increased PG; WT CRLS1 rescues mitochondrial morphology.
PMID:35147173
- Crls1 null mice: peri-implantation lethality; neuronal cKO -> neurodegeneration, abnormal cristae,
reduced ETC supercomplexes. PMID:31914590
- Cardiomyocyte cKO blocks postnatal CL increase, cristae and respiratory chain maturation, death
by 2 weeks; tafazzin cKO does not. PMID:42414597
- These are downstream consequences of CL loss; they support the CL biosynthesis BP but should not
generate separate BP annotations (cristae organization, heart development, etc.) for CRLS1.
Annotation decisions (summary)
- ACCEPT: GO:0043337 (all), GO:0032049 (all), GO:0005743 (all), GO:0005739 IDA/IBA/HTP.
- GO:0016780, GO:0008654, GO:0046474, GO:0016020: correct but general IEA -> ACCEPT (broad IEA
consistent with the CDP-type mechanism).
- GO:0031966 ISS: accept (IM is more specific, already present).
- GO:0003841 / GO:0047144 (Reactome TAS, LPA acyltransferase): REMOVE (wrong substrate; underlying
LPG acyltransferase claim single-lab and doubtful).
- GO:0036148 PG acyl-chain remodeling (Reactome TAS): UNDECIDED.